Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Liver Fibrosis Treatment Pipeline Review H2 2016

Monday, October 17, 2016 3:51
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Liver Fibrosis – Pipeline Review, H2 2016’, provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685897-liver-fibrosis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis 
- The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects 
- The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @ https://www.wiseguyreports.com/reports/685897-liver-fibrosis-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Liver Fibrosis Overview 9 
Therapeutics Development 10 
Pipeline Products for Liver Fibrosis – Overview 10 
Pipeline Products for Liver Fibrosis – Comparative Analysis 11 
Liver Fibrosis – Therapeutics under Development by Companies 12 
Liver Fibrosis – Therapeutics under Investigation by Universities/Institutes 15 
Liver Fibrosis – Pipeline Products Glance 16 
Clinical Stage Products 16 
Early Stage Products 17 
Liver Fibrosis – Products under Development by Companies 18 
Liver Fibrosis – Products under Investigation by Universities/Institutes 22 
Liver Fibrosis – Companies Involved in Therapeutics Development 23 
Advinus Therapeutics Ltd 23 
Akarna Therapeutics Ltd. 24 
Angion Biomedica Corp. 25 
Asubio Pharma Co., Ltd. 26 
aTyr Pharma, Inc. 27 
Beijing Kawin Technology Share-Holding Co., Ltd. 28 
BioLineRx, Ltd. 29 
Bioneer Corporation 30 
BiOrion Technologies B.V. 31 
Bird Rock Bio, Inc. 32 
Bristol-Myers Squibb Company 33 
Cellmid Limited 34 
ContraVir Pharmaceuticals, Inc. 35 
Dicerna Pharmaceuticals, Inc. 36 
Digna Biotech, S.L. 37 
Dr. Falk Pharma GmbH 38 
Dynavax Technologies Corporation 39 
Evotec AG 40 
Galectin Therapeutics, Inc. 41 
Genfit SA 42 
Gilead Sciences, Inc. 43 
GNI Group Ltd. 44 
HEC Pharm Co., Ltd. 45 
Immuron Limited 46 
Intercept Pharmaceuticals, Inc. 47 
INVENT Pharmaceuticals, Inc. 48 
Isarna Therapeutics GmbH 49 
KineMed, Inc. 50 
LG Life Science LTD. 51 
Nitto Denko Corporation 52 
Pfizer Inc. 53 
Pharmaxis Limited 54 
Promedior, Inc. 55 
Promethera Biosciences S.A. 56 
ProMetic Life Sciences Inc. 57 
Ribomic Inc. 58 
RXi Pharmaceuticals Corporation 59 
Silence Therapeutics Plc 60 
TCM Biotech International Corp 61 
Vascular Biogenics Ltd. 62 
Virobay Inc. 63 
XTuit Pharmaceuticals, Inc. 64 
Liver Fibrosis – Therapeutics Assessment 65 
Assessment by Monotherapy Products 65 
Assessment by Combination Products 66 
Assessment by Target 67 
Assessment by Mechanism of Action 71 
Assessment by Route of Administration 74 
Assessment by Molecule Type 76 
Drug Profiles 78 
ANG-3070 – Drug Profile 78 
ANG-3281 – Drug Profile 79 
Antisense RNAi Oligonucleotide for Liver Disease – Drug Profile 80 
Antisense RNAi Oligonucleotide for Liver Diseases – Drug Profile 81 
Antisense RNAi Oligonucleotide for Liver Fibrosis – Drug Profile 82 
Antisense RNAi Oligonucleotide for Liver Fibrosis – Drug Profile 83 
Antisense RNAi Oligonucleotide for Liver Fibrosis – Drug Profile 84 
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis – Drug Profile 85 
Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis – Drug Profile 86 
ASB-14780 – Drug Profile 87 
BL-1210 – Drug Profile 88 
BMS-986171 – Drug Profile 89 
BOT-162 – Drug Profile 90 
BOT-191 – Drug Profile 91 
CAB-102 – Drug Profile 92 
CPI-43132 – Drug Profile 94 
CT-140 – Drug Profile 97 
DB-036 – Drug Profile 98 
Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis – Drug Profile 99 
Drugs for Tissue Fibrosis – Drug Profile 100 
DV-1079 – Drug Profile 101 
F-351 – Drug Profile 103 
Gene Therapy for Liver Fibrosis – Drug Profile 105 
GMCT-01 – Drug Profile 106 
GRMD-02 – Drug Profile 110 
GS-444217 – Drug Profile 121 
HEC-585 – Drug Profile 122 
HepaStem – Drug Profile 123 
IMM-124E – Drug Profile 125 
INT-767 – Drug Profile 128 
INV-240 – Drug Profile 129 
ISTH-0047 – Drug Profile 130 
KW-0 – Drug Profile 132 
KW-012 – Drug Profile 133 
LC-280126 – Drug Profile 134 
melittin – Drug Profile 135 
Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis – Drug Profile 136 
MOR-8457 – Drug Profile 137 
MRI-1867 – Drug Profile 138 
ND-L02s0201 – Drug Profile 139 
norursodeoxycholic acid – Drug Profile 141 
noscapine – Drug Profile 142 
PBI-4050 – Drug Profile 143 
PRM-151 – Drug Profile 148 
Proteins for Liver Fibrosis – Drug Profile 153 
PXS-4820 – Drug Profile 154 
PXS-5033A – Drug Profile 155 
RBM-006 – Drug Profile 156 
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation – Drug Profile 157 
RXI-209 – Drug Profile 158 
RYI-018 – Drug Profile 159 
selonsertib – Drug Profile 160 
selonsertib + simtuzumab – Drug Profile 161 
Small Molecule for Liver Fibrosis – Drug Profile 162 
Small Molecule for Liver Fibrosis – Drug Profile 163 
Small Molecule to Agonize FXR for NASH and Liver Fibrosis – Drug Profile 164 
Small Molecule to Antagonize AlphaVBetaI for Fibrosis – Drug Profile 165 
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis – Drug Profile 166 
Small Molecules for Hepatic Fibrosis – Drug Profile 167 
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis – Drug Profile 168 
Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis – Drug Profile 169 
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis – Drug Profile 170 
TCM-808FB – Drug Profile 171 
TGFTX-4 – Drug Profile 172 
VB-201 – Drug Profile 173 
VB-703 – Drug Profile 176 
VBY-376 – Drug Profile 177 
VBY-825 – Drug Profile 178 
Liver Fibrosis – Dormant Projects 179 
Liver Fibrosis – Discontinued Products 183 
Liver Fibrosis – Product Development Milestones 184 
Featured News & Press Releases 184 
Appendix 193 
Methodology 193 
Coverage 193 
Secondary Research 193 
Primary Research 193 
Expert Panel Validation 193 
Contact Us 193 
Disclaimer 194

List of Tables 
Number of Products under Development for Liver Fibrosis, H2 2016 15 
Number of Products under Development for Liver Fibrosis – Comparative Analysis, H2 2016 16 
Number of Products under Development by Companies, H2 2016 17 
Number of Products under Development by Companies, H2 2016 (Contd..1) 18 
Number of Products under Development by Companies, H2 2016 (Contd..2) 19 
Number of Products under Investigation by Universities/Institutes, H2 2016 20 
Comparative Analysis by Clinical Stage Development, H2 2016 21 
Comparative Analysis by Early Stage Development, H2 2016 22 
Products under Development by Companies, H2 2016 23 
Products under Development by Companies, H2 2016 (Contd..1) 24 
Products under Development by Companies, H2 2016 (Contd..2) 25 
Products under Development by Companies, H2 2016 (Contd..3) 26 
Products under Investigation by Universities/Institutes, H2 2016 27 
Liver Fibrosis – Pipeline by Advinus Therapeutics Ltd, H2 2016 28 
Liver Fibrosis – Pipeline by Akarna Therapeutics Ltd., H2 2016 29 
Liver Fibrosis – Pipeline by Angion Biomedica Corp., H2 2016 30 
Liver Fibrosis – Pipeline by Asubio Pharma Co., Ltd., H2 2016 31 
Liver Fibrosis – Pipeline by aTyr Pharma, Inc., H2 2016 32 
Liver Fibrosis – Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 33 
Liver Fibrosis – Pipeline by BioLineRx, Ltd., H2 2016 34 
Liver Fibrosis – Pipeline by Bioneer Corporation, H2 2016 35 
Liver Fibrosis – Pipeline by BiOrion Technologies B.V., H2 2016 36 
Liver Fibrosis – Pipeline by Bird Rock Bio, Inc., H2 2016 37 
Liver Fibrosis – Pipeline by Bristol-Myers Squibb Company, H2 2016 38 
Liver Fibrosis – Pipeline by Cellmid Limited, H2 2016 39 
Liver Fibrosis – Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 40 
Liver Fibrosis – Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 41 
Liver Fibrosis – Pipeline by Digna Biotech, S.L., H2 2016 42 
Liver Fibrosis – Pipeline by Dr. Falk Pharma GmbH, H2 2016 43 
Liver Fibrosis – Pipeline by Dynavax Technologies Corporation, H2 2016 44 
Liver Fibrosis – Pipeline by Evotec AG, H2 2016 45 
Liver Fibrosis – Pipeline by Galectin Therapeutics, Inc., H2 2016 46 
Liver Fibrosis – Pipeline by Genfit SA, H2 2016 47 
Liver Fibrosis – Pipeline by Gilead Sciences, Inc., H2 2016 48 
Liver Fibrosis – Pipeline by GNI Group Ltd., H2 2016 49 
Liver Fibrosis – Pipeline by HEC Pharm Co., Ltd., H2 2016 50 
Liver Fibrosis – Pipeline by Immuron Limited, H2 2016 51 
Liver Fibrosis – Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 52 
Liver Fibrosis – Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 53 
Liver Fibrosis – Pipeline by Isarna Therapeutics GmbH, H2 2016 54 
Liver Fibrosis – Pipeline by KineMed, Inc., H2 2016 55 
Liver Fibrosis – Pipeline by LG Life Science LTD., H2 2016 56 
Liver Fibrosis – Pipeline by Nitto Denko Corporation, H2 2016 57 
Liver Fibrosis – Pipeline by Pfizer Inc., H2 2016 58 
Liver Fibrosis – Pipeline by Pharmaxis Limited, H2 2016 59 
Liver Fibrosis – Pipeline by Promedior, Inc., H2 2016 60 
Liver Fibrosis – Pipeline by Promethera Biosciences S.A., H2 2016 61 
Liver Fibrosis – Pipeline by ProMetic Life Sciences Inc., H2 2016 62 
Liver Fibrosis – Pipeline by Ribomic Inc., H2 2016 63 
Liver Fibrosis – Pipeline by RXi Pharmaceuticals Corporation, H2 2016 64 
Liver Fibrosis – Pipeline by Silence Therapeutics Plc, H2 2016 65 
Liver Fibrosis – Pipeline by TCM Biotech International Corp, H2 2016 66 
Liver Fibrosis – Pipeline by Vascular Biogenics Ltd., H2 2016 67 
Liver Fibrosis – Pipeline by Virobay Inc., H2 2016 68 
Liver Fibrosis – Pipeline by XTuit Pharmaceuticals, Inc., H2 2016 69 
Assessment by Monotherapy Products, H2 2016 70 
Assessment by Combination Products, H2 2016 71 
Number of Products by Stage and Target, H2 2016 73 
Number of Products by Stage and Mechanism of Action, H2 2016 77 
Number of Products by Stage and Route of Administration, H2 2016 80 
Number of Products by Stage and Molecule Type, H2 2016 82 
Liver Fibrosis – Dormant Projects, H2 2016 184 
Liver Fibrosis – Dormant Projects (Contd..1), H2 2016 185 
Liver Fibrosis – Dormant Projects (Contd..2), H2 2016 186 
Liver Fibrosis – Dormant Projects (Contd..3), H2 2016 187 
Liver Fibrosis – Discontinued Products, H2 2016 188

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685897

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.